A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas

Table 4 Patient background and molecular status of analysis for GBM cohort

Cohort	All^a	Cohort 1	Cohort 2	P-value^b
Total	453	260	193
Mean Age at diagnosis	61.0	59.3	63.3	0.0007
Sex M/F	249/204	152/108	97/96	0.0827
Location^c
Cereberal with frontal involvement	152 (34)	87 (33)	65 (34)	0.985
Cerebral (other)	277 (61)	160 (62)	117 (61)
Other	22 (5)	13 (5)	9 (5)
KPS
100	56 (12)	12 (5)	44 (23)	<0.0001
90	132 (29)	81 (31)	51 (26)
80	111 (25)	73 (28)	38 (20)
70	85 (19)	53 (20)	32 (17)
− 60	69 (15)	41 (16)	28 (15)
TERT/MGMT
Mut/Met	88 (19)	48 (18)	40 (21)	0.921
Mut/Un-met	175 (39)	100 (38)	75 (39)
Wt/Met	64 (14)	38 (15)	26 (13)
Wt/Un-met	126 (28)	74 (28)	52 (27)
Surgery
Removal	421 (93)	238 (92)	183 (95)
Biopsy only	32 (7)	22 (8)	10 (5)	0.178

^aIDH1/2 mutated cases were excluded for this analysis (see Materials and methods in the manuscript)
^bStudent’s t-test was applied for the statistical analysis of age, and Pearson’s chi-square test was done for others
^cData of Location was not available in 2 cases of Cohort2
F Female, GBM glioblastoma, KPS Karnofsky Performance Status, M Male, Met MGMT methylated, Mut TERT mutated, N/A not available, Un-met MGMT unmethylated, wt TERT wild-type

ISSN: 2051-5960